GlassScriptPhysician profile
Carolyn M Kassabian
NPI 1851335152
$4,064.64
in general payments reported to CMS, 2019-2025
28 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $197 · 2021: $338 · 2022: $405 · 2023: $656 · 2024: $927 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,750 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.63 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.79 | 2021-2025 | |
| Genzyme Corporation | $619.63 | 2020-2025 | |
| Lilly USA, LLC | $398.30 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $315.61 | 2020-2025 | Tremfya |
| Amgen INC. | $249.20 | 2020-2025 | Otezla |
| Pfizer INC. | $205.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $194.42 | 2019-2025 | |
| Celgene Corporation | $191.99 | 2019 | |
| Galderma Laboratories, L.P. | $187.61 | 2019-2025 | Dysport, Nemluvio |
| Glaxosmithkline, LLC. | $156.11 | 2021-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $147.74 | 2023-2025 | Prolastin-C Liquid |
| Ucb, INC. | $120.53 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $119.12 | 2021-2025 | Winlevi, Ilumya |
| Leo Pharma INC. | $58.67 | 2022-2025 | Anzupgo |
| Incyte Corporation | $53.73 | 2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $52.17 | 2024-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $41.55 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $38.82 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $32.35 | 2024 | Vtama |
| Medtronic Vascular, INC. | $21.69 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.27 | 2021 | |
| Arcutis Biotherapeutics, INC. | $20.73 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $18.36 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.98 | 2025 | Cabtreo, Siliq, Jublia |
| Mylan Specialty L.P. | $16.01 | 2023 | Yupelri |
| Phadia US INC. | $15.86 | 2023 | Immunocap |
| Inogen, INC. | $15.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Kassabian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.